Blood cancer immune therapy trial ends early after just 2 patients
NCT ID NCT05933070
First seen Apr 12, 2026 · Last updated May 13, 2026 · Updated 5 times
Summary
This early-stage study tested a new drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to see if it was safe and to find the best dose. Only 2 people took part before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Attikon University General Hospital
Athens, Attica, 124 62, Greece
-
Sheffield Teaching Hospitals NHS FT - Royal Hallamshire Hospital
Sheffield, Sheffield, S10 2RX, United Kingdom
-
University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, S016 6YD, United Kingdom
Conditions
Explore the condition pages connected to this study.